Hyperbaric Oxygen Therapy for Post Traumatic Stress Disorder - a Pragmatic, Double Blinded Randomized Trial
NCT07473362 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 72
Last updated 2026-03-16
Summary
Post-traumatic stress disorder (PTSD), affecting approximately 6% of the general population and up to one-third of individuals exposed to combat zones and disasters, is a significant contributor to morbidity and mortality among IDF personnel. Hyperbaric oxygen therapy (HBOT), in which patients breathe oxygen at a partial pressure higher than 1 atmosphere in a hyperbaric chamber, has been investigated in the context of treating a wide range of neuropsychiatric disorders, including PTSD and mild traumatic brain injury (mTBI).
Four controlled studies conducted in patients with mTBI, about half of whom also suffered from PTSD, have yielded conflicting conclusions regarding the potential efficacy of hyperbaric therapy. A single study involving approximately 30 patients with PTSD without mTBI demonstrated significant clinical improvement; however, it was characterized by several methodological limitations-chief among them the absence of blinding or a placebo control. None of the studies conducted to date have reported long-term findings (beyond one year), included patients with a short duration of symptoms ("early PTSD"), or included female participants.
The aim of the proposed study is to conduct a prospective, double-blind, controlled investigation of the biological effect of hyperbaric therapy in PTSD, continuously throughout the hyperbaric treatment course, at the end of treatment, and during a substantial follow-up period of two years after treatment completion.
We intend to include adult participants who are capable of providing informed consent and who meet DSM-5 diagnostic criteria for PTSD. In order to maintain a pragmatic study with high external validity, exclusion criteria will be limited to those indicating risk (concrete suicidality, or a history of manic or psychotic disorder) or factors likely to impair treatment efficacy (incompatibility with hyperbaric chamber treatment, inability to complete the full treatment protocol, or pregnancy). Participants who miss a substantial number of treatments (five consecutively or one-third of the total treatments) will be withdrawn from the study.
The primary outcome measure will be the CAPS-5 questionnaire. In addition, PTSD symptom questionnaires, surveys assessing cognitive, executive, affective functioning, and health-related quality of life will be administered. An exploratory outcome will focus on sleep quantity and quality and physiological monitoring using wearable devices, currently considered the most promising biomarker in the context of PTSD.
Following enrollment and the provision of informed consent, balanced randomization will be performed with respect to covariates previously described as potential confounders (such as age, duration, and severity of symptoms, …). Participants will receive 60 hyperbaric treatments, five days per week, at either 2.0 atmospheres or 2.5 atmospheres. Both the participants and the evaluating clinical staff will be blinded to treatment allocation.
Conditions
- PTSD - Post Traumatic Stress Disorder
Interventions
- PROCEDURE
-
Hyperbaric Oxygen Therapy
The treatment will be carried out in a HAUX STARMED multi-place pressure chamber (by HAUX LIFESUPPORT SYSTEMS, Cuxhaven, Germany) containing three sections (12+2+6 places, respectively). Ambulatory blood pressure measurement will be performed by an ambulatory blood pressure monitor (ABPM) model F11 (by SUNTECH). Measurement of sleep continuity and physiological monitoring will be performed using a combined pulse-oxymetry and accelerometry wearable device such as the Oura ring (Oulu. Finland).
Sponsors & Collaborators
-
Medical Corps, Israel Defense Force
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-03-01
- Primary Completion
- 2027-08-31
- Completion
- 2027-08-31
Countries
- Israel
Study Locations
More Related Trials
-
Enhanced Hippocampal Neuroplasticity for Surfacing of Inaccessible Traumatic Memories in Veterans With PTSD
NCT05883397 ·Status: UNKNOWN ·Phase: NA
-
Hypnotherapeutic Olfactory Conditioning for Posttraumatic Stress Disorder (PTSD)
NCT00784771 ·Status: COMPLETED ·Phase: NA
-
The Effect of Using the Combat Attention App on the Risk of Post-traumatic Symptoms
NCT06710145 ·Status: NOT_YET_RECRUITING
-
Attention Control Treatment for Post Traumatic Stress Disorder ׂ(PTSD)
NCT02945709 ·Status: COMPLETED ·Phase: NA
-
Post Traumatic Stress Disorder (PTSD) Hyperarousal Symptoms Treated With Physiological Stress Management
NCT00855816 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Short-Term Recall and Reprocess Therapy for Post Traumatic Stress Disorder (PTSD)
NCT06826937 ·Status: RECRUITING ·Phase: NA
-
Psychotherapy Treatment of Deployment-Related PTSD in Primary Care Settings
NCT00974402 ·Status: COMPLETED ·Phase: NA
-
Investigation of the Freespira Breathing System in the Treatment of Post Traumatic Stress Disorder (PTSD)
NCT03039231 ·Status: COMPLETED ·Phase: NA
-
Prolonged Exposure Versus Treatment as Usual in Chronic Posttraumatic Stress Disorder Combat and Terror Related Patients
NCT00229372 ·Status: COMPLETED ·Phase: NA
-
MentalGym™ and NeuroBrave™ Guided Wearable-Assisted Physiology Regulation Training for PTSD (PRTP)
NCT07462312 ·Status: RECRUITING ·Phase: NA
-
Non-Trauma Intervention to Treat PTSD for Veterans and Service Members Suffering From a TBI
NCT07351305 ·Status: RECRUITING ·Phase: NA
-
Evaluation of Psilocybin-assisted Psychotherapy (PaP) for the Treatment of Post-traumatic Stress Disorder (PTSD) in Military Veterans
NCT05876481 ·Status: UNKNOWN ·Phase: PHASE2
-
Home-Delivered Attention Control Treatment for Post Traumatic Stress Disorder (PTSD)
NCT04228133 ·Status: COMPLETED ·Phase: NA
-
In-Home Exposure Therapy for Veterans With Post Traumatic Stress Disorder (PTSD)
NCT03110302 ·Status: COMPLETED ·Phase: NA
-
Neurofeedback Prevention For Early Stress Related Adversity
NCT02477722 ·Status: UNKNOWN ·Phase: NA
-
A Randomized Cross Over Trial of Two Treatments for Sleep Apnea in Veterans With Post-Traumatic Stress Disorder
NCT01569022 ·Status: COMPLETED ·Phase: NA
-
Predictors of Treatment Response to Fluoxetine in PTSD Following a Recent History of War Zone Stress Exposure
NCT00633685 ·Status: UNKNOWN ·Phase: PHASE4
-
A Randomized Cross Over Trial of Two Treatments for Obstructive Sleep Apnea in Veterans With Post Traumatic Stress Disorder
NCT01535586 ·Status: UNKNOWN ·Phase: PHASE4
-
Targeted Accelerated TMS for Post-Traumatic Stress Disorder
NCT07245641 ·Status: RECRUITING ·Phase: NA
-
Prolonged Exposure Therapy Versus Active Psychotherapy in Treating Post-Traumatic Stress Disorder in Adolescents
NCT00183690 ·Status: COMPLETED ·Phase: PHASE1
-
Exposure Therapy For Veterans With PTSD And Panic Attacks
NCT01033136 ·Status: COMPLETED ·Phase: NA
-
Deep Brain Stimulation for Treatment Refractory PTSD
NCT03416894 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Effects of CPAP Therapy on PTSD Symptoms
NCT02019914 ·Status: COMPLETED
-
Evaluation of a Yoga Intervention for Post-Traumatic Stress Disorder
NCT00962403 ·Status: COMPLETED ·Phase: NA
-
Prevention of Combat-related PTSD Using Attention Bias Modification (ABM): A Randomized Controlled Trial
NCT01723215 ·Status: COMPLETED ·Phase: NA